

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of treating sepsis comprising the steps of administering to a patient with sepsis a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 2 (withdrawn): A method of reducing the risk of sepsis comprising the steps of administering to a patient at risk of sepsis comprises a therapeutically effective amount of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

Claim 3 (currently amended): A method of producing a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, comprising the steps of blending constituents including at least one lipid, liquefying a blended mixture and homogenising the liquefied blended mixture to produce a product wherein greater than 35% of the total energy of the composition is provided by lipid wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 4 (currently amended): A composition comprising at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 5 (canceled)

Claim 6 (original): A composition according to claim 4, which comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 7 (original): A composition according to claim 4, which comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 8 (original): A composition according to claim 4 for enteral administration which includes at least one component selected from the group consisting of an acceptable carrier, diluent and adjuvant.

Claim 9 (original): The method of claim 1 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 10 (currently amended): A method of treating inflammatory shock comprising the step of administering to a patient suffering inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 11 (original): The method of claim 1 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 12 (canceled)

Claim 13 (original): The method of claim 1 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 14 (original): The method of claim 1 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 15 (original): The method of claim 1 wherein the composition is administered enterally.

Claim 16 (withdrawn): A method for reducing the risk of inflammatory shock comprising the step of administering to a patient at risk of inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

Claim 17 (withdrawn): The method of claim 2 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 18 (withdrawn): The method of claim 2 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 19 (withdrawn): The method of claim 2 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 20 (withdrawn): The method of claim 2 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 21 (withdrawn): The method of claim 2 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 22 (withdrawn): The method of claim 2 wherein the composition is administered enterally.

Claim 23 (original): The method of claim 3 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 24 (original): The method of claim 3 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 25 (canceled)

Claim 26 (withdrawn): The method of claim 3 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 27 (withdrawn): The method of claim 3 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 28 (withdrawn): The method of claim 3 wherein the composition is administered enterally.

Claim 29 (withdrawn): The method of claim 10 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 30 (withdrawn): The method of claim 10 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 31 (withdrawn): The method of claim 10 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 32 (withdrawn): The method of claim 10 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 33 (withdrawn): The method of claim 10 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 34 (withdrawn): The method of claim 10 wherein the composition is administered enterally.

Claim 35 (withdrawn): The method of claim 16 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 36 (withdrawn): The method of claim 16 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 37 (withdrawn): The method of claim 16 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 38 (withdrawn): The method of claim 16 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α -linolenic acid, EPA, DPA and DHA.

Claim 39 (withdrawn): The method of claim 16 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ -linolenic acid (18:3, n-6), dihomo- γ -linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 40 (withdrawn): The method of claim 16 wherein the composition is administered enterally.